Download MendeleyFrom PIM1 to PI3K delta via GSK3 beta : Target Hopping through the Kinome.
Henley, Z.A., Bax, B.D., Inglesby, L.M., Champigny, A., Gaines, S., Faulder, P., Le, J., Thomas, D.A., Washio, Y., Baldwin, I.R.(2017) ACS Med Chem Lett 8: 1093-1098
- PubMed: 29057057
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00296
- Primary Citation of Related Structures:
5OY4, 6AYD - PubMed Abstract:
Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3β through consideration of differences in the ATP binding pockets. Continued kinase cross-screening showed PI3Kδ activity in a series of 4,6-disubstituted indazole compounds, and subsequent structure-activity relationship exploration led to the discovery of an indole-containing lead compound as a potent PI3Kδ inhibitor with selectivity over the other PI3K isoforms.
Organizational Affiliation:
Refractory Respiratory Inflammation DPU, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.
